Brief: Coya Therapeutics Announces Completion Of Enrollment In Phase 2 Study Of Low Dose Interleukin-2 In Patients With Alzheimer’S Disease
09/10/2023 13:27
Oct 9 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS (COYA) ANNOUNCES COMPLETION OF
ENROLLMENT IN A
WELL-CONTROLLED PHASE 2 STUDY OF LOW DOSE INTERLEUKIN-2 (LD
IL-2) IN PATIENTS WITH ALZHEIMER’S DISEASE (AD)
* COYA THERAPEUTICS INC: TOPLINE RESULTS OF STUDY ARE
ANTICIPATED
TO BE REPORTED IN SUMMER 2024
Source text for Eikon: ID:nBwbwdSrFa
Further company coverage: COYA.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)